A total of 60 infants with bronchiolitis were included from January 2018 to December 2019. They were randomly divided into the observation group and the control group， with 30 cases in each. The control group received routine treatment while the observation group received budesonide combined with terbutaline sulfate atomization inhalation. The time of disappearance of clinical symptoms， the changes of inflammatory factors before and after treatment and the therapeutic effect were compared between the two groups.

There were significant differences in the disappearance time of cough， wheezing， dyspnea and lung wheezing between the observation group and the control group （P < 0.05）； TNF in children-α， the levels of IL-6 and IL-8 inflammatory factors decreased after treatment. Compared with those before the treatment， the difference was statistically significant （P < 0.05）. The indexes of the observation group were lower than those of the control group （P < 0.05）； The total effective rate of the observation group was higher than that of the control group （93.3% vs 70.0%）， and the difference was statistically significant （P < 0.05）.

Budesonide combined with terbutaline sulfate atomization inhalation in the treatment of infant bronchiolitis can significantly improve the level of inflammatory factors in children and is beneficial to accelerate the disappearance of symptoms. The effect is reliable and worthy of clinical promotion.

纳入的病例资料来源于巨野县人民医院于2018年1月—2019年12月收治的毛细支气管炎患儿，共60例，随机分为观察组与对照组，每组各30例，对照组行常规治疗，观察组治疗方案为布地奈德联合硫酸特布他林雾化吸入。比较两组患儿临床症状消失时间、治疗前后炎症因子水平变化情况及治疗效果。

观察组与对照组患儿在咳嗽、憋喘、呼吸困难以及肺部哮鸣音症状消失时间方面的差异有统计学意义（P < 0.05）；两组患儿TNF-α、IL-6、IL-8等炎症因子水平经过治疗均降低，与治疗前比较，差异有统计学意义（P < 0.05），治疗后观察组各项指标较对照组低，差异有统计学意义（P < 0.05）；观察组较对照组总体有效率高（93.3% VS 70.0%），差异有统计学意义（P < 0.05）。

布地奈德联合硫酸特布他林雾化吸入治疗婴幼儿毛细支气管炎，对患儿炎症因子水平改善显著，有利于加快症状消失，效果可靠，值得临床推广。